Table 1 Patient characteristics at HAM-net enrollment
Characteristic | All (n = 547) | BDSG 0 (n = 44) | BDSG I (n = 358) | BDSG II (n = 127) | BDSG III (n = 18) |
|---|---|---|---|---|---|
Age at enrollment (years), mean (SD) | 61.9 (10.7) | 57.5 (13.9) | 61.7 (10.4) | 63.2 (9.9) | 68.5 (9.6) |
Age at disease onset (years), mean (SD) | 45.3 (14.8) | 46.3 (15.0) | 45.2 (14.1) | 44.0 (16.0) | 53.4 (15.7) |
Disease duration (years), mean (SD) | 16.6 (11.6) | 11.1 (8.5) | 16.4 (11.2) | 19.2 (12.7) | 14.3 (11.7) |
Female sex, n (%) | 408 (74.6%) | 31 (70.5%) | 259 (72.3%) | 103 (81.1%) | 15 (83.3%) |
OMDS, median (IQR) | 5.0 (4–6) | 4.0 (2–5) | 5.0 (4–6) | 6.0 (5–8) | 10.0 (6–12) |
Urinary symptom score | Â | Â | Â | Â | Â |
HAM-BDSS | Â | Â | Â | Â | Â |
Total score, mean (SD) | 16.0 (10.1) | 6.9 (6.6) | 19.1 (9.1) | 10.3 (9.6) | – |
median (IQR) | 16.0 (7–24) | 7.0 (1–9.8) | 19.0 (13–26) | 8.5 (2–17.8) | – |
Storage symptom score, mean (SD) | 7.6 (5.3) | 3.3 (2.8) | 8.7 (5.1) | 6.0 (5.4) | – |
Median (IQR) | 7.0 (3–12) | 3.0 (1–5) | 9.0 (5–13) | 4.0 (1.3–10) | – |
Voiding symptom score, mean (SD) | 8.0 (6.7) | 3.6 (4.9) | 10.3 (6.2) | 4.3 (6.0) | – |
Median (IQR) | 7.0 (1–15) | 1.0 (0–5.8) | 10.0 (5–15) | 0 (0–8) | – |
I-PSS, mean (SD) | 13.5 (9.1) | 6.1 (5.7) | 16.5 (8.2) | 8.0 (8.4) | – |
Median (IQR) | 13.0 (5–21) | 6.0 (1–8) | 17.0 (10–23) | 4.0 (1–15) | – |
OABSS, mean (SD) | 6.0 (4.1) | 2.7 (2.5) | 6.7 (4.0) | 5.0 (4.2) | – |
Median (IQR) | 6.0 (2–9) | 2.5 (1–4) | 7.0 (3–10) | 4.0 (2–8) | – |
ICIQ-SF, mean (SD) | 6.0 (6.1) | 2.3 (4.3) | 6.6 (6.0) | 5.7 (6.3) | 6.5 (7.5) |
Median (IQR) | 5.0 (0–11) | 0 (0–3) | 7.0 (0–11) | 3.5 (0–11) | 6.0 (0–13.5) |
Steroid therapy, n (%) | 235 (43.0%) | 13 (29.5%) | 167 (46.6%) | 48 (37.8%) | 7 (38.9%) |
Medication for urinary dysfunction, n (%) | 186 (34.0%) | 0 (0.0%) | 145 (40.5%) | 38 (29.9%) | 3 (16.7%) |
α1 adrenergic-receptor antagonists, n (%) | 68 (12.4%) | 0 (0.0%) | 60 (16.8%) | 8 (6.3%) | 0 (0.0%) |
β3-adrenoceptor agonists, n (%) | 31 (5.7%) | 0 (0.0%) | 27 (7.5%) | 4 (3.1%) | 0 (0.0%) |
Anticholinergics, n (%) | 62 (11.3%) | 0 (0.0%) | 43 (12.0%) | 19 (15.0%) | 0 (0.0%) |
Cholinergic agonists, n (%) | 27 (4.9%) | 0 (0.0%) | 23 (6.4%) | 4 (3.1%) | 0 (0.0%) |
Others, n (%) | 34 (6.2%) | 0 (0.0%) | 22 (6.1%) | 9 (7.1%) | 3 (16.7%) |